thirty-eight premenopausal breast cancer patients were treated for periods up to 12 months with a sustained-release formulation of the luteinizing hormone-releasing hormone agonist goserelin [ zoladex , ( d-ser ( but ) 6azgly10-lh-rh ) ; 3.6 mg depot every 4 weeks ] either alone or in combination with the antioestrogen tamoxifen citrate ( nolvadex 40 mg/day ) .
C0120107
goserelin
C0023610
lh-rh